ライフサイエンスコーパス: tenofovir disoproxil fumarate

1 amide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate).

2 men (both regimens include emtricitabine and tenofovir disoproxil fumarate).

3 (581 with tenofovir alafenamide and 292 with tenofovir disoproxil fumarate).

4 namide and 19 [7%] of 288 patients receiving tenofovir disoproxil fumarate).

5 /F/tenofovir alafenamide and 867 given E/C/F/tenofovir disoproxil fumarate).

6 come region of enrollment, hypertension, and tenofovir disoproxil fumarate.

7 osted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate.

8 n coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

9 despite consistent use of emtricitabine and tenofovir disoproxil fumarate.

10 non-inferiority of tenofovir alafenamide to tenofovir disoproxil fumarate.

11 remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate.

12 ir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate.

13 versus in those remaining on one containing tenofovir disoproxil fumarate.

14 argin of tenofovir alafenamide compared with tenofovir disoproxil fumarate.

15 improved renal and bone safety compared with tenofovir disoproxil fumarate.

16 in patients switched from emtricitabine with tenofovir disoproxil fumarate.

17 n with initiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate.

18 inavir/ritonavir, or efavirenz/emtricitabine/tenofovir disoproxil fumarate.

19 rkers of renal safety than emtricitabine and tenofovir disoproxil fumarate.

20 rom pivotal studies using oral emtricitabine-tenofovir disoproxil fumarate.

21 fenamide 0.01 mg/dL [95% CI 0.00 to 0.02] vs tenofovir disoproxil fumarate 0.02 mg/dL [0.00 to 0.04],

22 creatinine increases than those given E/C/F/tenofovir disoproxil fumarate (0.08 vs 0.12 mg/dL; p<0.0

23 21 were in those assigned emtricitabine plus tenofovir disoproxil fumarate (0.48 cases per 100 person

24 73, 95% confidence interval [CI] 0.56-0.96), tenofovir disoproxil fumarate (0.68, 95% CI 0.49-0.95),

25 Any plaque was negatively associated with tenofovir disoproxil fumarate (0.71, 95% CI 0.51-0.99).

26 (tenofovir alafenamide 40 [14%] patients vs tenofovir disoproxil fumarate 14 [10%] patients), nasoph

27 r (400/100 mg) twice daily and emtricitabine/tenofovir disoproxil fumarate (200/300 mg) once daily.

28 mly assigned (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine

29 0 mg; once-daily oral fixed-dose combination tenofovir disoproxil fumarate 300 mg and emtricitabine 2

30 , 200 mg, or 400 mg once a day or to receive tenofovir disoproxil fumarate 300 mg once a day; each al

31 oral doses of tenofovir alafenamide 25 mg or tenofovir disoproxil fumarate 300 mg, each with matching

32 ) ritonavir (RTV) or standard of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200

33 or once-daily oral fixed-dose combination of tenofovir disoproxil fumarate 300 mg, emtricitabine 200

34 rticipants were given combination tablets of tenofovir disoproxil fumarate (300 mg) and emtricitabine

35 ee-drug regimen of dolutegravir (50 mg) plus tenofovir disoproxil fumarate (300 mg) and emtricitabine

36 namide group), or emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) tablets daily, wi

37 virenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching pl

38 ivirine (25 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching pl

39 10 mg) daily or continued therapy containing tenofovir disoproxil fumarate (300 mg).

40 lus combination emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate, 300 mg/d.

41 similar to that seen with oral emtricitabine/tenofovir disoproxil fumarate (94.0%; 55.1%-99.2%).

42 de was associated with more weight gain than tenofovir disoproxil fumarate, abacavir, or zidovudine.

43 ted with each additional year of exposure to tenofovir disoproxil fumarate (adjusted incidence rate r

44 was not significantly different from that of tenofovir disoproxil fumarate alone (hazard ratio [HR] 0

45 ety and efficacy of daily oral emtricitabine-tenofovir disoproxil fumarate among HIV-seronegative men

46 ciated with noncalcified/mixed plaque, while tenofovir disoproxil fumarate and efavirenz were negativ

47 Daily, oral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC

48 ry of Food and Drug Safety in Korea approved tenofovir disoproxil fumarate and emtricitabine (TDF/FTC

49 Preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (Truvada

50 disoproxil fumarate monotherapy or combined tenofovir disoproxil fumarate and emtricitabine and whet

51 effect in a context that also includes oral tenofovir disoproxil fumarate and emtricitabine as an op

52 eness of the new product in addition to oral tenofovir disoproxil fumarate and emtricitabine as compa

53 As pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine for the

54 f pre-exposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine in 2499

55 tonavir-boosted atazanavir plus coformulated tenofovir disoproxil fumarate and emtricitabine once a d

56 th darunavir/ritonavir and 2 nucleos(t)ides (tenofovir disoproxil fumarate and emtricitabine or abaca

57 g (one tablet) orally twice daily, each with tenofovir disoproxil fumarate and emtricitabine orally o

58 lled three-group phase 3 trial of daily oral tenofovir disoproxil fumarate and emtricitabine plus ten

59 acquisition, the protective efficacy of oral tenofovir disoproxil fumarate and emtricitabine relies o

60 ent film colour), and lamivudine tablets and tenofovir disoproxil fumarate and emtricitabine tablets

61 atinine clearance and the number of doses of tenofovir disoproxil fumarate and emtricitabine taken pe

62 Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine was adop

63 ing that they are non-inferior to daily oral tenofovir disoproxil fumarate and emtricitabine.

64 Patients started RAL in combination with tenofovir disoproxil fumarate and lamivudine after initi

65 iated with less renal and bone toxicity than tenofovir disoproxil fumarate and might improve the long

66 In contrast, tenofovir disoproxil fumarate and tenofovir alafenamide

67 In contrast, tenofovir disoproxil fumarate and tenofovir alafenamide

68 We quantified tenofovir disoproxil fumarate and tenofovir concentratio

69 BMS-986001 had similar efficacy to that of tenofovir disoproxil fumarate and was associated with a

70 ir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate and were followed up for H

71 amide and 36 [13%] of 288 patients receiving tenofovir disoproxil fumarate) and AST (20 [3%] of 577 p

72 ses of CAB LA, 6 received oral emtricitabine/tenofovir disoproxil fumarate, and 10 were untreated.

73 retroviral therapy (ART; combined efavirenz, tenofovir disoproxil fumarate, and emtricitabine).

74 ovir alafenamide was non-inferior to that of tenofovir disoproxil fumarate, and had improved bone and

75 n, tenofovir alafenamide was non-inferior to tenofovir disoproxil fumarate, and had improved bone and

76 l density than a standard regimen containing tenofovir disoproxil fumarate, and might be a treatment

77 cells and EMP had greater TF activity, while tenofovir disoproxil fumarate- and tenofovir alafenamide

78 e relative to combination emtricitabine plus tenofovir disoproxil fumarate as PrEP.

79 ir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate as PrEP.

80 bolite to target cells more efficiently than tenofovir disoproxil fumarate at a lower dose, thereby r

81 -six CHB patients who started treatment with tenofovir disoproxil fumarate at a public hospital in Et

82 /ADAPT) of oral PrEP with emtricitabine plus tenofovir disoproxil fumarate at a research centre in Ca

83 lso extend to HIV-negative individuals using tenofovir disoproxil fumarate-based pre-exposure prophyl

84 t the magnitude of benefit of PrEP with oral tenofovir disoproxil fumarate-based therapy to reduce th

85 il fumarate compared with emtricitabine plus tenofovir disoproxil fumarate, but show that once-daily

86 Tenofovir disoproxil fumarate can cause renal and bone t

87 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (combined ART).

88 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compared with a boosted pr

89 a slight difference in HIV-1 protection with tenofovir disoproxil fumarate compared with emtricitabin

90 d trial of PrEP with oral emtricitabine plus tenofovir disoproxil fumarate compared with placebo in m

91 Nearly all (97.6%) patients received tenofovir disoproxil fumarate-containing ART, in line wi

92 copies per mL), aged 60 years or older, on a tenofovir disoproxil fumarate-containing regimen and wer

93 ) or to carry on taking one of four previous tenofovir disoproxil fumarate-containing regimens (tenof

94 min or greater, and were taking one of four tenofovir disoproxil fumarate-containing regimens for at

95 improved renal and bone safety compared with tenofovir disoproxil fumarate-containing regimens.

96 articipants were randomized 1:1:1 to receive tenofovir-disoproxil fumarate (DF) plus emtricitabine, a

97 disoproxil fumarate; one patient assigned to tenofovir disoproxil fumarate did not receive the treatm

98 8 versus 130 (93%) of 140 patients receiving tenofovir disoproxil fumarate (difference 1.8% [95% CI -

99 Nine participants switched from E/C/F/tenofovir disoproxil fumarate (E/C/F/TDF 150/150/200/300

100 mide (E/C/F/tenofovir alafenamide) or 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxi

101 TC/TDF) with that of efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF).

102 group, 275 (78%) of 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and dolute

103 and dolutegravir group; 4.3 kg [6.7] in the tenofovir disoproxil fumarate, emtricitabine, and dolute

104 citabine, and dolutegravir group, 351 to the tenofovir disoproxil fumarate, emtricitabine, and dolute

105 wer among infants exposed from conception to tenofovir disoproxil fumarate, emtricitabine, and efavir

106 up, and 258 (74%) of 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and efavir

107 dolutegravir group, and 2.3 kg [7.0] in the tenofovir disoproxil fumarate, emtricitabine, and efavir

108 bine, and dolutegravir group, and 351 to the tenofovir disoproxil fumarate, emtricitabine, and efavir

109 Ten (3%) of 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and efavir

110 oninferior and potentially safer option than tenofovir disoproxil fumarate-emtricitabine (F/TDF) for

111 aive participants were randomized to receive tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) pl

112 This study estimated the number of daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) do

113 phylaxis (PrEP) interventions worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) fo

114 ment-naive individuals randomized equally to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pl

115 P utilization as the number of people taking tenofovir disoproxil fumarate/emtricitabine for HIV prev

116 Daily tenofovir disoproxil fumarate/emtricitabine is recommend

117 ed ART-naive participants were randomized to tenofovir disoproxil fumarate/emtricitabine plus atazana

118 s who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure

119 tenofovir disoproxil fumarate monotherapy or tenofovir disoproxil fumarate/emtricitabine was associat

120 se inhibitors (NRTIs; abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabine) and a third

121 e-exposure prophylaxis (PrEP) in the form of tenofovir-disoproxil-fumarate/emtricitabine is being imp

122 acy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) with that

123 r alafenamide and 12 (4%) patients receiving tenofovir disoproxil fumarate experienced serious advers

124 d eGFR included traditional risk factors and tenofovir disoproxil fumarate exposure.

125 men and had been on daily emtricitabine and tenofovir disoproxil fumarate for 8 months presented wit

126 ies per mL) on efavirenz, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months befo

127 s per mL) on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months befo

128 inferior efficacy to daily emtricitabine and tenofovir disoproxil fumarate for HIV prevention, and th

129 namide was non-inferior to emtricitabine and tenofovir disoproxil fumarate for HIV prevention, as the

130 nofovir alafenamide versus emtricitabine and tenofovir disoproxil fumarate for HIV prevention.

131 fumarate (TDF) and combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious

132 ated that combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure p

133 ophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) decreases the ri

134 Background therapies were emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in P007; abacavi

135 e prophylaxis (PrEP) with emtricitabine plus tenofovir disoproxil fumarate (FTC/TDF) or TDF alone red

136 f daily oral co-formulated emtricitabine and tenofovir disoproxil fumarate (FTC/TDF).

137 p<0.0001) and 93% for the emtricitabine plus tenofovir disoproxil fumarate group (0.07, 0.02-0.23; p<

138 and 15 participants in the emtricitabine and tenofovir disoproxil fumarate group (0.34 infections per

139 amide group and in 444 (93%) assigned to the tenofovir disoproxil fumarate group (adjusted difference

140 r alafenamide group and -0.10% (3.39) in the tenofovir disoproxil fumarate group (between-group diffe

141 enamide group compared with 307 (93%) in the tenofovir disoproxil fumarate group (difference 1.3%, 95

142 r alafenamide group and -0.73% (3.21) in the tenofovir disoproxil fumarate group (difference 2.04% [1

143 risk reduction in HIV-1 acquisition for the tenofovir disoproxil fumarate group (HR 0.15, 95% CI 0.0

144 per mL, compared with 88 (89%) of 99 in the tenofovir disoproxil fumarate group (modified intention-

145 lated to study treatment; one patient in the tenofovir disoproxil fumarate group died, but this was n

146 fovir alafenamide (2%) and three (1%) in the tenofovir disoproxil fumarate group discontinued due to

147 namide group and one (2%) participant in the tenofovir disoproxil fumarate group had an adverse event

148 de group and 96 (33%) of 292 patients in the tenofovir disoproxil fumarate group had grade 3 or 4 lab

149 ruption and thrombocytopenia) and two in the tenofovir disoproxil fumarate group had study drug-relat

150 e group and 784 (90%) of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1

151 vir disoproxil fumarate-containing regimens (tenofovir disoproxil fumarate group) for 96 weeks.

152 e tenofovir alafenamide group and 314 to the tenofovir disoproxil fumarate group).

153 f 2693 participants in the emtricitabine and tenofovir disoproxil fumarate group).

154 h matched placebo tablets (emtricitabine and tenofovir disoproxil fumarate group).

155 fovir alafenamide group; and one (2%) in the tenofovir disoproxil fumarate group).

156 of 437 in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group.

157 e tenofovir alafenamide group and 477 to the tenofovir disoproxil fumarate group.

158 alafenamide group compared with those in the tenofovir disoproxil fumarate group.

159 our [7%]), and arthralgia (four [7%]) in the tenofovir disoproxil fumarate group.

160 e group compared with 37 (12%) of 314 in the tenofovir disoproxil fumarate group; none of these were

161 enofovir alafenamide and 294 (94%) of 313 on tenofovir disoproxil fumarate had maintained less than 5

162 alafenamide and nine (6%) patients receiving tenofovir disoproxil fumarate had serious adverse events

163 s given E/C/F/tenofovir alafenamide or E/C/F/tenofovir disoproxil fumarate had virological success.

164 Antiretroviral regimens containing tenofovir disoproxil fumarate have been associated with

165 in bone mineral density than those receiving tenofovir disoproxil fumarate (hip -0.29% [95% CI -0.55

166 lafenamide was superior to emtricitabine and tenofovir disoproxil fumarate in all six prespecified bo

167 pen-label study of rilpivirine/emtricitabine/tenofovir disoproxil fumarate in ART-naive HIV controlle

168 daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fumarate in combination with emtric

169 or to continuing rilpivirine, emtricitabine, tenofovir disoproxil fumarate in maintaining viral suppr

170 the efficacy and safety of BMS-986001 versus tenofovir disoproxil fumarate in treatment-naive patient

171 ily use of PrEP with oral emtricitabine plus tenofovir disoproxil fumarate in women.

172 ections, 31 occurred in individuals assigned tenofovir disoproxil fumarate (incidence 0.71 cases per

173 Compared with tenofovir disoproxil fumarate, individuals in the BMS-98

174 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (integrase inhibitor regim

175 ty, pharmacokinetics, and acceptability of a tenofovir disoproxil fumarate intravaginal ring used con

176 Emtricitabine with tenofovir disoproxil fumarate is a standard-of-care nucl

177 However, tenofovir disoproxil fumarate is associated with renal a

178 re prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate is highly effective agains

179 Daily emtricitabine/tenofovir disoproxil fumarate is recommended as preexpos

180 ophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate is used to prevent the sex

181 HIV in Kampala, Uganda, and receiving daily tenofovir disoproxil fumarate/lamivudine were recruited.

182 or the prevention of HIV infection with oral tenofovir disoproxil fumarate monotherapy or combined te

183 reased risk of HIV infection, PrEP with oral tenofovir disoproxil fumarate monotherapy or tenofovir d

184 o 100 mg, 67 to 200 mg, and 66 to 400 mg) or tenofovir disoproxil fumarate (n=101).

185 ir alafenamide (n=2694) or emtricitabine and tenofovir disoproxil fumarate (n=2693).

186 eive either tenofovir alafenamide (n=333) or tenofovir disoproxil fumarate (n=330).

187 , and tenofovir alafenamide (n=111 [66%]) or tenofovir disoproxil fumarate (n=56 [34%]).

188 enamide vs 22 [8%] of 292 patients receiving tenofovir disoproxil fumarate), nasopharyngitis (56 [10%

189 mg of raltegravir twice daily and 300 mg of tenofovir disoproxil fumarate once daily as a backbone.

190 to tenofovir alafenamide and 141 assigned to tenofovir disoproxil fumarate; one patient assigned to t

191 transcriptase inhibitors: emtricitabine and tenofovir disoproxil fumarate or abacavir and lamivudine

192 SVR12 among patients receiving either tenofovir disoproxil fumarate or abacavir as part of the

193 should be followed; adjustment should avoid tenofovir disoproxil fumarate or boosted protease inhibi

194 re offered rerandomisation in a 1:1 ratio to tenofovir disoproxil fumarate or emtricitabine plus teno

195 4410 (99.6%) of 4427 couples received tenofovir disoproxil fumarate or emtricitabine plus teno

196 oxil fumarate, but show that once-daily oral tenofovir disoproxil fumarate or emtricitabine plus teno

197 ravir combined with emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide),

198 exposure prophylaxis (PrEP), with daily oral tenofovir disoproxil fumarate or tenofovir disoproxil fu

199 the antiretrovirals abacavir sulphate (ABC), tenofovir disoproxil fumarate, or tenofovir alafenamide.

200 among participants receiving efavirenz with tenofovir disoproxil fumarate (p=0.001) but not those re

201 Second, the effectiveness of tenofovir disoproxil fumarate plus emtricitabine varies

202 hylaxis (PrEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an

203 l tissue exposure by the third daily dose of tenofovir disoproxil fumarate plus emtricitabine.

204 given a new PrEP agent or oral coformulated tenofovir disoproxil fumarate plus emtricitabine.

205 open-label study of daily oral emtricitabine-tenofovir disoproxil fumarate PrEP among 50 HIV-uninfect

206 r disoproxil fumarate and emtricitabine plus tenofovir disoproxil fumarate PrEP in HIV-1 uninfected i

207 n (efavirenz combined with emtricitabine and tenofovir disoproxil fumarate) previously recommended by

208 ir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate (protease inhibitor based

209 al ring that releases the tenofovir prodrug, tenofovir disoproxil fumarate, provided 100% protection

210 regimen and 402 (92%) of 437 assigned to the tenofovir disoproxil fumarate regimen (difference -2.0%,

211 eived one dose of study drug and were on the tenofovir disoproxil fumarate regimen before screening w

212 ir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate regimens both provide high

213 We assessed the efficacy of single-agent tenofovir disoproxil fumarate relative to combination em

214 of 99 and one (1%) of 99 patients receiving tenofovir disoproxil fumarate, respectively.

215 azanavir/ritonavir, lopinavir/ritonavir, and tenofovir disoproxil fumarate, respectively.

216 12 were assigned to receive the tenofovir disoproxil fumarate ring and five were assigne

217 days 14 and 28 compared with baseline in the tenofovir disoproxil fumarate ring group but not the pla

218 Two participants in the tenofovir disoproxil fumarate ring group completed 3 mon

219 grade 2 adverse events were reported in the tenofovir disoproxil fumarate ring group.

220 d finding of ulcerations is specific to this tenofovir disoproxil fumarate ring or generalisable to o

221 V negative were randomly assigned (3:1) to a tenofovir disoproxil fumarate ring or placebo ring.

222 e increased for up to 6 years of exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazana

223 sease associated with cumulative exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazana

224 lights the importance of expanding access to tenofovir disoproxil fumarate-sparing regimens in resour

225 After adjustment, persons who had ever used tenofovir disoproxil fumarate (TDF) (1.40; 1.15-1.70) or

226 enofovir prodrugs - TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) -

227 a 3-arm randomized, pharmacokinetic study of tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine

228 prophylaxis (PrEP) using the antiretroviral tenofovir disoproxil fumarate (TDF) alone or in combinat

229 oviral preexposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF) and combination emtr

230 y randomized to the efavirenz /emtricitabine/tenofovir disoproxil fumarate (TDF) and dolutegravir/emt

231 e randomly assigned to take a combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (F

232 Oral tenofovir disoproxil fumarate (TDF) and emtricitabine (F

233 the NAPs REP 2139 or REP 2165 combined with tenofovir disoproxil fumarate (TDF) and pegylated interf

234 ed drug combinations have been marketed, and tenofovir disoproxil fumarate (TDF) and tenofovir alafen

235 In the present study, we show that tenofovir disoproxil fumarate (TDF) and tenofovir alafen

236 emtricitabine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumarate (TDF) as a 3-drug, single-

237 viral therapy currently receive some form of tenofovir disoproxil fumarate (TDF) as part of their HIV

238 ose DOR at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate (TDF) at 300 mg (DOR/3TC/T

239 The approved tenofovir disoproxil fumarate (TDF) dose of 300 mg every

240 Tenofovir disoproxil fumarate (TDF) has been linked to r

241 itis B e antigen positive patients receiving tenofovir disoproxil fumarate (TDF) in an open-label, lo

242 Despite widespread use of tenofovir disoproxil fumarate (TDF) in pregnant and brea

243 The efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother-t

244 Tenofovir disoproxil fumarate (TDF) is active against la

245 Tenofovir disoproxil fumarate (TDF) is an established nu

246 Tenofovir disoproxil fumarate (TDF) is associated with p

247 Tenofovir disoproxil fumarate (TDF) is commonly used in

248 Tenofovir disoproxil fumarate (TDF) is one of the nucleo

249 Exposure to tenofovir disoproxil fumarate (TDF) may cause renal toxi

250 Tenofovir disoproxil fumarate (TDF) plays a pivotal role

251 Clinical studies of systemic tenofovir disoproxil fumarate (TDF) PrEP revealed reduce

252 emtricitabine (FTC) resistance and increased tenofovir disoproxil fumarate (TDF) susceptibility.

253 change in participants switching from E/C/F/tenofovir disoproxil fumarate (TDF) to E/C/F/TAF.

254 from patients with rapid or slow response to tenofovir disoproxil fumarate (TDF) treatment, have been

255 d, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks ge

256 Although tenofovir disoproxil fumarate (TDF) use has increased as

257 ravir, cobicistat, emtricitabine (E/C/F) and tenofovir disoproxil fumarate (TDF) who switched to E/C/

258 Replacing tenofovir disoproxil fumarate (TDF) with tenofovir alafe

259 differ among patients receiving LDV/SOF and tenofovir disoproxil fumarate (TDF) without a protease i

260 2a for 96 weeks and combination therapy with tenofovir disoproxil fumarate (TDF) would increase hepat

261 Once-daily oral tenofovir disoproxil fumarate (TDF), alone or combined w

262 lone, MVC plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.

263 MVC only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (contro

264 nd 7 had M184V/I (0.1%), despite high use of tenofovir disoproxil fumarate (TDF), emtricitabine, and

265 ug of tenofovir and a potential successor of tenofovir disoproxil fumarate (TDF), has been approved i

266 ed trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtr

267 l to demonstrate that a novel gel containing tenofovir disoproxil fumarate (TDF), the more potent pro

268 ophylaxis (PrEP) with a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodr

269 It is unknown if tenofovir disoproxil fumarate (TDF), which is often cofo

270 We compared maraviroc (MVC)- to tenofovir disoproxil fumarate (TDF)-containing ART.

271 importance of renal and endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicit

272 cluding the clinically approved formulation, tenofovir disoproxil fumarate (TDF).

273 ylactic efficacy of oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF).

274 ion in persons living with HIV (PLWH) taking tenofovir disoproxil fumarate (TDF).

275 s and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC),

276 PLWH receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/

277 men with symptomatic HSV-2 infection to oral tenofovir disoproxil fumarate (TDF)/placebo vaginal gel,

278 andomly assigned to groups given either oral tenofovir disoproxil fumarate (TDF, 300 mg) and placebo

279 AD from the DOR groups (DOR/lamivudine [3TC]/tenofovir disoproxil fumarate [TDF] or DOR [100 mg daily

280 Tenofovir disoproxil fumarate (tenofovir) has been assoc

281 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir) might be a saf

282 ed protease inhibitor and emtricitabine plus tenofovir disoproxil fumarate (tenofovir) regimen to cof

283 r plasma concentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone a

284 cells more efficiently at a lower dose than tenofovir disoproxil fumarate, thereby reducing systemic

285 ility of switching from a regimen containing tenofovir disoproxil fumarate to elvitegravir, cobicista

286 n patients switching from emtricitabine with tenofovir disoproxil fumarate to emtricitabine with teno

287 nsity of switching from a regimen containing tenofovir disoproxil fumarate to one containing tenofovi

288 responses were independent of emtricitabine/tenofovir disoproxil fumarate use.

289 d tenofovir alafenamide to emtricitabine and tenofovir disoproxil fumarate was established if the upp

290 amide-containing regimen from one containing tenofovir disoproxil fumarate was non-inferior for maint

291 afenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in mainta

292 prevention efficacy with emtricitabine plus tenofovir disoproxil fumarate was not significantly diff

293 previous use of PrEP with emtricitabine and tenofovir disoproxil fumarate were not excluded.

294 ndividuals on cART (predominantly containing tenofovir disoproxil fumarate) were also more likely to

295 improved renal and bone safety compared with tenofovir disoproxil fumarate when used for HIV treatmen

296 e 200 mg emtricitabine with 200 mg or 300 mg tenofovir disoproxil fumarate, while remaining on the sa

297 erior to the 195 (67%) of patients receiving tenofovir disoproxil fumarate who had HBV DNA less than

298 either 25 mg tenofovir alafenamide or 300 mg tenofovir disoproxil fumarate with matching placebo.

299 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matching placebo.

300 ofovir alafenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, with 800 (92%) of 866 pat

301 tenofovir alafenamide was as efficacious as tenofovir disoproxil fumarate, with reduced bone and ren